^
    Back
    Association details:
    Biomarker:NT5C2 mutation
    Cancer:Acute Lymphocytic Leukemia
    Drug:mercaptopurine (DNA synthesis inhibitor, PRPP amidotransferase inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    New
    Source:
    Academic Commons
    Title:

    Structure Function Analysis of Drug Resistance Driver Mutations in Acute Lymphoblastic Leukemia

    Excerpt:
    Furthermore, NT5C2 mutant proteins conferred resistance to 6-mercaptopurine and 6-thioguanine chemotherapy drugs when expressed in ALL lymphoblasts, suggesting NT5C2 is responsible for the inactivation of nucleoside-analog chemotherapy drugs.
    DOI:
    10.7916/D8S46XQD